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The immunosuppressive mechanism of action of intravenous immune globulin (IVIG) has remained
enigmatic despite the many years of clinical experience in the treatment of autoimmunity. In this issue
of Immunity, Park-Min et al. (2007) demonstrate that IVIG engagement of FcgRIII receptor on mono-
cytes inhibits the cellular response to interferon-g.Intravenous immune globulin (IVIG)
has been used for the treatment of
antibody (Ab)-mediated inflammatory
diseases for more than two decades.
It is particularly effective in autoim-
mune thrombocytopenia (ITP) where
response rates approach 75%, and
its clinical utility extends to many other
autoimmune conditions including va-
culitides, blistering skin diseases, de-
myelinating diseases, and dermato-
myositis. The effectiveness of IVIG
across a range of autoimmune condi-
tions, encompassing various patho-
logical mechanisms, suggests a broad
immunomodulatory mechanism of ac-
tion, beyond merely inhibiting Ab-trig-
gered inflammation. In this issue of
Immunity, Park-Min et al. (2007) report
that IVIG blocks cellular activation by
interferon-g (IFN-g), a proinflammatory
cytokine of central importance to the
cellular immune response, thus pro-
viding a unique immunosuppressive
mechanism that may contribute to
the broad therapeutic activity of IVIG.
Gamma globulin is the IgG fraction
of human blood products pooled
from thousands of donors. As replace-
ment therapy in immunodeficiency
states, its rationale is straightforward:
to restore circulating IgG concentra-
tions to more normal amounts. IVIG
treatment in autoimmunity increases
circulating IgG concentrations tran-
siently before redistributing in extra-
vascular sites. Some mechanistic
hypotheses propose that antibody
specificities of donor IgG contribute
to efficacy; however, most studies
have found that the active component
of IVIG is contained in the Fc domain
rather than the antigen-binding
F(ab’)2 domains. Interactions of mono-
meric IgG (the dominant molecular4 Immunity 26, January 2007 ª2007 Elsespecies of IVIG) with FcRn have been
proposed to contribute to IVIG effi-
cacy, and indeed administration of
IVIG results in diminution of circulating
autoantibody concentrations by 20%–
40% (Hansen and Balthasar, 2002),
but this would appear insufficient to
by itself account for the rapid and dra-
matic improvements seen clinically in
ITP. Other studies have instead impli-
cated polymeric species rather than
monomeric IgG as the active compo-
nent of IVIG. The potential sources of
polymeric species include Ig dimers
formed by idiotypic antibodies, which
have specificities for each other, non-
specific IgG aggregation, and immune
complexes formed in vivo between do-
nor antibodies and recipient antigens.
Indeed, the argument for the therapeu-
tic relevance of immune complexes is
best provided by the fact that the
clinical activity of IVIG is recapitulated
in Rh+ individuals by administration of
polyclonal Rh (D) antibodies. These
antibodies bind surface epitopes on
red blood cells forming large partic-
ulate immune complexes in vivo,
namely Ab-opsonized red blood cells.
Dramatic platelet count recoveries
indicate that platelet phagocytosis
was substantially inhibited in vivo.
Similarly administration of smaller im-
mune complexes formed ex vivo or
in vivo can mimic the IVIG therapeutic
response (Siragam et al., 2005).
Both conventional FcgRs and com-
plement interact with Fc domains and
mediate the biological response to
immune complexes, including anti-
genic uptake and the regulation of
the activation response of both
myeloid and lymphoid cells. In the
IVIG response, several responsible
immunomodulatory pathways may bevier Inc.relevant (Figure 1). Competitive block-
ade of activating FcgRs by IVIG-gen-
erated immune complexes is the sim-
plest mechanistic explanation for the
protective capacity of IVIG in Ab-trig-
gered inflammatory states. Blockade
would occur rapidly, immediately
dampening ongoing destruction and
potentially explaining the rapidity of
some clinical responses. Indeed, anti-
bodies that block the activating
FcgR, FcgRIII, have been shown to
be effective in murine studies (Sa-
muelsson et al., 2001) as well as in pilot
clinical studies (Soubrane et al., 1993).
However, this mechanism would be
transient, limited kinetically by the
clearance of the ‘‘therapeutic’’ IVIG
immune complex component. Thus,
sustained immunomodulatory activity
is not likely to result from immediate
competitive blockade.
The two-step model proposed by
Ravetch established a framework for
the cellular basis of a sustained anti-
inflammatory IVIG effect. In the KBxN
model of arthritis, IVIG interacts with a
CSF-1-dependent ‘‘sensor’’ cell, which
secondarily upregulates the expres-
sion of inhibitory FcgRIIB on a second
CSF-1-independent inflammatory ‘‘ef-
fector’’ cell (Bruhns et al., 2003). This
increase in inhibitory FcgRIIB expres-
sion on inflammatory macrophages
would oppose activating FcgR signal-
ing, thereby downmodulating the
antibody-triggered inflammatory re-
sponse. Siragam et al. provided further
support for the two-step model: trans-
ferred IVIg-treated CD11c+ spleno-
cytes inhibited the development of ITP
in wild-type but not FcgRIIB-deficient
adoptive recipients (Siragam et al.,
2006). These transferred regulatory
dendritic cells (DCs) thus exemplify
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PreviewsFigure 1. Immunosuppressive Mechanisms of IVIG
IVIG suppresses inflammatory responses passively by competing for occupancy with IgG receptors or can actively induce immunosuppression
through cellular signaling pathways that inhibit cellular activation. Passive inhibition is as follows. (1) IgG monomers compete with soluble auto-
antibody for occupancy with FcRn, thereby enhancing the clearance of pathogenic autoantibodies. (2) IVIG-derived Ig aggregates, dimers, and
ICs compete with pathogenic ICs for occupancy of activating FcgRs, thereby blocking immune activation. (3) F(ab’)2 fragments binds the complement
fragments C3a and C5a, neutralizing their proinflammatory activity. Active inhibition is as follows. (4) IVIG interacts with sensor macrophages and/or
DCs via activating FcgRs, which subsequently suppress activation of effector macrophages, via upregulation of FcgRIIB. (5) Dimeric FcR crosslinking
block subsequent ITAM-mediated activation responses. Inhibitory signaling through activating (6) FcgRI or (7) FcgRIII signaling can block TLR or IFN-g
activation, respectively. Inhibition of the IFN-g response is due to PU.1-mediated transcriptional repression of IFN-gR2.an IVIG-stimulated sensor cell, confer-
ring IVIG immunodulatory activity
upon FcgRIIB-bearing cellular ef-
fectors in recipient animals. Interest-
ingly, the immunomodulatory effect
required FcRg expression in trans-
ferred IVIG-stimulated DCs, implying
that ITAM (immunoreceptor tyrosine-
based activation motif)-mediated sig-
naling triggers the inhibitory pathway
in sensor cells. What then is the rele-
vant ITAM-mediated inhibitory signal-
ing pathway triggered by IVIG?
In this issue of Immunity, Park-
Min et al. (2007) provide a potential
mechanism for the sustained immuno-
modulatory activity of IVIG, namely
induction of an IFN-g refractory state.
After >10 hr of IVIG exposure in vitro,
murine and human macrophages failed
to inducibly phosphorylate STAT1
in response to IFN-g. Downstream
consequences were apparent; IVIG-treated cells failed to induce expres-
sion of STAT-1 target genes; and
IVIG-treated mice failed to control in-
fection with Listeria monocytogenes,
an intracellular pathogen whose elimi-
nation in vivo requires an intact IFN-g
response.
IVIG engagement of the activating
FcgR, FcgRIII, were required in both
human and mouse macrophages for
the induction of the IFN-g refractory
state. Thus, sustained (>10 hr) cross-
linking of FcgRIII with either ICs, ag-
gregated Fc domains, or FcgRIII anti-
bodies was sufficient to recapitulate
the IVIG-triggered IFN-g refractory
state in vitro. Importantly, because
IFN-g is a key cytokine contributing
to the cellular inflammatory response,
this link offers insight into the potential
of IVIG to inhibit, not merely antibody-
mediated autoimmune states, but also
chronic inflammatory conditions inImmunitywhich injury is caused by T cells as
well as pathogenic antibodies.
For now it is not clear how suppres-
sion of IFN-g signaling fits into the two-
cell sequential model. Kinetics of the
induction of the IFN-g refractory state
were slow and treatments involved
several hours to as much as 2 days
of prior IVIG exposure before IFN-g
stimulation, arguing for the potential
generation of autocrine and paracrine
factors. However, soluble factors pro-
duced by IVIG-regulated wild-type
cells were insufficient by themselves
to confer IVIG inhibitory activity on
FcgRIII-deficient cells in mixed culture
systems, and furthermore, FcgRIIB
expression was not required. The
work of Park-Min et al. (2007) argues
instead for cell-intrinsic ITAM-medi-
ated inhibitory signaling. IVIG is shown
to downregulate the expression of
the nonligand-binding subunit of the26, January 2007 ª2007 Elsevier Inc. 5
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Importantly, ectopic expression of
IFN-gR2 rescued the normal IFN-g re-
sponse in IVIG-treated cells, consis-
tent with the hypothesis that IFN-gR2
downmodulation is the proximal cause
of the IVIG-induced IFN-g refractory
state. IFN-gR2 expression is con-
trolled by the Ets family of transcription
factors, and the authors further show
that the DNA binding activity of the
Ets family transcription factor PU.1,
acting as a transcriptional repressor,
increased upon IVIG treatment, result-
ing in attenuation of IFN-gR2 expres-
sion. The mechanism regulating PU.1
activity is not clear although changes
in PU.1 protein expression were ruled
out. Because many other genes are
regulated by Ets family transcription
factors, one could speculate that
suppression of IFN-gR2 might be
one of several manifestations of an
ITAM-induced generalized tolerogenic
transcriptional program. Thus, a
unique immunosuppressive pathway
has been identified in triggered by
sustained ITAM-mediated signaling
through FcgRIII.
The concept that ITAM-mediated
signaling can promote either activation
or inhibitory cellular outcomes has
well-accepted precedent in B cell
and T cell antigen receptors signaling
in lymphocytes, where the quality and
amplitude dictates tolerance versus
activation. In DCs or other myeloid
cells, this concept of ‘‘paradoxical’’
ITAM-inhibitory signaling has gathered
recent support (Hamerman and Lanier,
2006). Engagement of several mem-
bers of the immunoglobulin (Ig) super-
family, including FcaRI, Siglec-H,
TREM-2, NKp44, PIR-A, or ILT-7,
leads to impaired TLR-mediated acti-
vation through the participation of the
ITAM-mediated adapters DAP12 or
Fc3RI g. Thus, ITAM-inhibitory signal-
ing appears to be a common pathway
employed by both conventional Fc
receptor family members and other
Ig-family immunoreceptors expressed
on myeloid cells. In interpreting the
dual-functionality of FcaRI signal-
ing (Hamerman and Lanier, 2006;
Pasquier et al., 2005), it has been pro-
posed that cellular activation results6 Immunity 26, January 2007 ª2007 Elsevfrom high-affinity ligands-high-signal-
strength interactions (e.g., multivalent
clustering), whereas inhibitory re-
sponses instead result from low-affin-
ity ligands-low-signal-strength ligands
(e.g., mono- or divalent clustering),
with the amount of FcR g phophoryla-
tion, determining downstream activa-
tory or inhibitory outcome. Inter-
estingly, monomeric Ig occupancy
in vivo is predicted for both FcaRI
and the high-affinity FcgRI, suggesting
that both monomeric IgA and IgG may
induce sustained inhibitory signaling in
vivo (Sutterwala et al., 1998). One
might alternatively hypothesize that
IVIG inhibitory responses result in-
stead from sustained engagement of
activating FcgRs by low-valency ICs
present in IVIG. However, it should be
noted that in other inhibitory ITAM
immunoreceptor systems, higher-
order clustering induces inhibitory re-
sponses, arguing against a general
paradigm for discriminating activation
versus inhibitory signaling exclusively
based on strength-of-signal alone.
Thus, the understanding of the mecha-
nistic basis for activation versus inhib-
itory signaling remains incomplete and
further study may reveal additional sig-
naling partnerships.
The signaling pathway triggered by
FcgRIII described by Park-Min et al.
(2007) appears nonconventional be-
cause it is maintained in the face of
pharmacologic inhibition of syk, the
critical proximal protein tyrosine ki-
nase that promotes cellular activation
events by FcRg. Furthermore, IFN-g
refractoriness was sustained despite
the genetic absence of the most likely
candidate inhibitory phosphatases
SHP-1, SHP-2, or SHIP. Thus, one
can anticipate the involvement of ei-
ther unique intracellular partners in
FcRg inhibitory signaling or the recruit-
ment of non-FcgR cooperating cell-
surface receptors bound by IVIG. The
recent work of the Ravetch group (Ka-
neko et al., 2006) describing two dis-
tinct glycoform IgG subtypes distin-
guished by the presence or absence
of sialation offers a potential clue to
the existence of an IVIG receptor dis-
tinct from FcgR that binds sialated
IgG and suggests the provocativeier Inc.hypothesis that the IVIG response is
the manifestation of the normal physi-
ological response to anti-inflammatory
immunoglobulins produced during
times of health. Thus, in the steady-
state, or possibly in the latter stages
of infection when antibodies are pres-
ent in excess, IgG-derived ITAM-
mediated inhibitory signaling through
FcgRIII would dampen the response
to IFN-g, thereby promoting tolerance
by keeping the cellular cytokine-driven
inflammatory response in check. Be-
cause IVIG is far from an optimized
therapeutic, pharmacologic efforts to
capitalize on the FcgRIII-mediated in-
hibition of the IFN-g response identi-
fied here might be predicted to widen
the circle of individuals benefiting
from FcgR targeted therapeutics to
include patients with common Th1-
type-driven inflammatory diseases
including rheumatoid arthritis and
multiple sclerosis.
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